IceCure Medical Ltd. develops and markets an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. IceCure Medical Ltd. is based in CAESAREA, Israel.
| Revenue (Most Recent Fiscal Year) | $3.23M |
| Net Income (Most Recent Fiscal Year) | $-14.65M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.34 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.62 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -410.22% |
| Return on Equity (Trailing 12 Months) | -111.27% |
| Return on Assets (Trailing 12 Months) | -81.41% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.97 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.54 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.03 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.27 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.06 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.32 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.30 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 45.62M |
| Free Float | 44.51M |
| Market Capitalization | $27.82M |
| Average Volume (Last 20 Days) | 1.13M |
| Beta (Past 60 Months) | 0.48 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.44% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.62% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |